CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
naltrexone plus bupropiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01982643
NCT01982643Phase 2Completed
CompareCT.gov

CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder

Walter Ling·interventional·Posted Nov 13, 2013·Updated Mar 23, 2020

In Brief

A Phase 2 clinical trial evaluating naltrexone plus bupropion for Methamphetamine Use Disorder. Completed, enrolled 49 participants across 3 sites.

Detailed Summary

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), The Emmes Company, LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 13, 2013
Enrollment StartNov 1, 2013
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.6 years ago

Interventions

naltrexone plus bupropiondrug

Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.